Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MNOV
SellHot AirMediciNova, Inc. · Healthcare · United States · $71M · Avg Vol: $83K/d
23
StockRankGet insider-trade alerts
Q
30
V
28
M
50
P/E (TTM)
—
ROE
-25.6%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1.0M | 0 | 0.4M | -36.0% | 0.9M | 0.8M | 0.5M | 10.5% |
| EPS | -0.29 | -0.17 | -0.23 | -0.24 | — | -0.21 | -0.28 | -0.45 | — |
| Shares | 49.0M | 49.0M | 49.0M | 49.2M | +0.4% | 49.2M | — | — | — |
| Debt | 0.2M | 0.2M | 0.2M | 0.2M | 7.3% | 0.1M | — | — | — |
| Equity | 70.2M | 62.4M | 52.5M | 41.6M | -16.0% | — | — | — | — |
| Op CF | -12.9M | -7.4M | -10.6M | -9.8M | — | -9.1M | — | — | — |
| Inv CF | -40.0M | 39.9M | -697 | -2.9K | — | — | — | — | — |
| Fin CF | 7.9K | 0 | 0 | 0.2M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+29.9%
SMA 50SMA 200
Close
$1.74
RSI (14)
73.4
52W High
$1.96
From 52W High
0.9%
SCORE BREAKDOWN
Quality
30
ROIC
-30.9%24.3
ROE
-25.6%27.9
GP/Assets
0.8%12.2
Op. Margin
-554.3%9.7
FCF/Assets
-21.5%19.9
Piotroski
211.9
Int. Cover
—N/A
D/E Ratio
0.00x90.8
Current Ratio
8.75x85.0
Value
28
P/E (TTM)
—N/A
EV/EBITDA
-4.6x25.0
P/FCF
—N/A
P/B
2.2x59.5
P/S
87.2x7.2
Div Yield
—N/A
Momentum
50
52W High %
89%84.7
RS 6M
10%75.2
SMA 50/200
0.98x51.6
EPS Rev 4W
-4.7%14.1
EPS Rev 12W
—N/A
EPS Improve
-114%4.3
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$71M
P/E (Forward)
-3.6x
Gross Margin
37.7%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MNOV are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MNOV | MediciNova, Inc.(you) | $71M | 23 | Sell |
| ACET | Adicet Bio, Inc. | $85M | 23 | Sell |
| RNXT | RenovoRx, Inc. | $75M | 26 | Sell |
| PMVP | PMV Pharmaceuticals, Inc. | $65M | 19 | Strong Sell |
| XBIT | XBiotech Inc. | $69M | 27 | Sell |
| ATRA | Atara Biotherapeutics, Inc. | $92M | 23 | Sell |
| NRXS | NeurAxis, Inc. | $75M | 18 | Strong Sell |
| LONA | LeonaBio, Inc. | $75M | 18 | Strong Sell |
| APLM | Apollomics, Inc. | $77M | 28 | Sell |
| CSBR | Champions Oncology, Inc. | $68M | 30 | Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%